drugset / Trial / NCT00388960
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung cancer.
Timeline
- Start
- 2006-11-01
- Primary completion
- 2010-04-01
- Completion
- 2010-12-01
Publications
- Background O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.
- Background Liddell RP, Evans NS. May-Thurner syndrome. Vasc Med. 2018 Oct;23(5):493-496. doi: 10.1177/1358863X18794276. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amrubicin | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Amrubicin | Small molecule | 45 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 200 mg/m2 | Intravenous |